Lung Carcinoma

In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC)

PMID 41104928 · Le et al., 2025 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Osimertinib was effective in achieving a partial response in a patient with stage IV non-small cell lung cancer metastasis in the brain harboring ERBB2 exon 19 c.2262_2264delinsTCC, p.(L755P) variant.… (full text at CIViC)

PMID 37197637 · Jonsdottir et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In the multicohort phase 1b Beamion LUNG-1 trial (NCT04886804) of zongertinib in HER2-mutant NSCLC, three cohorts were evaluated by mutation type and prior therapy. In cohort 1 (n = 75; HER2-TKD mutat… (full text at CIViC)

PMID 40293180 · Heymach et al., 2025 · Open in CIViC

In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

In a phase 2 trial, 152 previously-treated metastatic NSCLC patients harboring mutations in ERBB2 (HER2) were treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 m… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

The authors report a case series where two patients with lung adenocarcinoma tumors harbored ERBB2 variant V659E (exon 17). Both cases achieved partial response to Trastuzumab deruxtecan (T-DXd). The… (full text at CIViC)

PMID 40873587 · Meng et al., 2025 · Open in CIViC

A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion. Afatinib monotherapy resulted… (full text at CIViC)

PMID 26559459 · Li et al., 2015 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC)

PMID 41104928 · Le et al., 2025 · Open in CIViC

Two lung cancer cell lines, 11_18 and Ma-24, were found to have significantly increased growth when treated with heregulin (HRG)‐α compared to other growth factors. Pertuzumab was found to significan… (full text at CIViC)

PMID 17627612 · Sakai et al., 2007 · Open in CIViC

Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Prote… (full text at CIViC)

PMID 26689995 · Umelo et al., 2016 · Open in CIViC

The goal of this study, was to find the predictive effect of ERCC1, RRM1 and LRP expression on the effectiveness of gemcitabine concomitant with nedaplatin, as a form of treatment, with patients who h… (full text at CIViC)

PMID 25227833 · Qiu et al., 2014 · Open in CIViC

Expression level of ERCC1 was evaluated in 61 NSCLC samples with RT-qPCR. Kaplan-Meier analysis showed that low expression of ERCC1 was associated with longer median survival time (17.3 versus 10.9 mo… (full text at CIViC)

PMID 16980606 · Ceppi et al., 2006 · Open in CIViC

In this review article, the median survival of non-small cell lung cancer patients with low levels of ERCC1, treated with platinum-based therapies was significantly prolonged as compared to those with… (full text at CIViC)

PMID 16807441 · Rosell et al., 2006 · Open in CIViC

The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three prev… (full text at CIViC)

PMID 19470925 · Gandara et al., 2009 · Open in CIViC

In a retrospective pan-cancer ICI-treated cohort from MSKCC (cohort 3, n = 1661), ERCC2/ERCC3/ERCC4/ERCC5-mutated tumors demonstrated improved OS vs ERCC-WT tumors (HR 0.54, 95% CI 0.42-0.70; p < 0.00… (full text at CIViC)

PMID 37626083 · Chen et al., 2023 · Open in CIViC

Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoter… (full text at CIViC)

PMID 26894620 · Bauer et al., 2017 · Open in CIViC

EGFR activity was markedly decreased during the evolution of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, with a concomitant increase of ERRFI1(Mig6), a negative regulator of EGFR… (full text at CIViC)

PMID 23935914 · Chang et al., 2013 · Open in CIViC

Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advance… (full text at CIViC)

PMID 26893365 · Hong et al., 2016 · Open in CIViC

In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC)

PMID 23182986 · Kim et al., 2013 · Open in CIViC

Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC)

PMID 25433983 · Jiang et al., 2015 · Open in CIViC

Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and… (full text at CIViC)

PMID 24302556 · Malchers et al., 2014 · Open in CIViC

Study of FGFR1 inhibitor AZD4547 in NSCLC xenograft models. FGFR1-amplified models that overexpress FGFR1 (detected by IHC) were strongly inhibited by 25mg/kg AZH4547 (P≤0.0001). Another FGFR1-ampli… (full text at CIViC)

PMID 23082000 · Zhang et al., 2012 · Open in CIViC

FGFR2 C491S was identified as selectively conferring futibatinib resistance in FGFR-dependent NCI-H1581 cells and was independently validated by drug-treated cell-viability and FGFR phosphorylation ex… (full text at CIViC)

PMID 41361008 · Tangermann et al., 2025 · Open in CIViC